Serine/Threonine Kinase MLK4 Determines Mesenchymal Identity in Glioma Stem Cells in an NF-κB-dependent Manner

Cancer Cell

Volumn 29, Issue 2, 2016, Pages 201-213

  Kim, Sung Hak ^a   Ezhilarasan, Ravesanker ^c   Phillips, Emma ^d   Gallego Perez, Daniel ^e,f   Sparks, Amanda ^g   Taylor, David ^g   Ladner, Katherine ^e   Furuta, Takuya ^h   Sabit, Hemragul ^h   Chhipa, Rishi ⁱ   Cho, Ju Hwan ^g   Mohyeldin, Ahmed ^g   Beck, Samuel ^j   Kurozumi, Kazuhiko ^k   Kuroiwa, Toshihiko ^l   Iwata, Ryoichi ^m   Asai, Akio ^m   Kim, Jonghwan ^j   Sulman, Erik P ^c   Cheng, Shi Yuan ⁿ   Lee, L James ^e,f   Nakada, Mitsutoshi ^h   Guttridge, Denis ^e   DasGupta, Biplab ⁱ   Goidts, Violaine ^d   Bhat, Krishna P ^c   Nakano, Ichiro ^a,b   more..

^a University of Alabama at Birmingham   (United States)

^b UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^c UNIVERSITY OF TEXAS   (United States)

^d GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^e OHIO STATE UNIVERSITY   (United States)

^f The Ohio State University   (United States)

^g OHIO STATE UNIVERSITY   (United States)

^h KANAZAWA UNIVERSITY   (Japan)

ⁱ CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

^j University of Texas at Austin   (United States)

^k OKAYAMA UNIVERSITY   (Japan)

^l OSAKA MEDICAL COLLEGE   (Japan)

^m KANSAI MEDICAL UNIVERSITY   (Japan)

ⁿ NORTHWESTERN UNIVERSITY   (United States)

more..

Author keywords

Cancer stem cell; Epithelial to mesenchymal transition; Glioblastoma; Proneural mesenchymal transition

Indexed keywords

IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MIXED LINEAGE KINASE; MIXED LINEAGE KINASE 4; PROTEIN SERINE THREONINE KINASE; UNCLASSIFIED DRUG; MITOGEN ACTIVATED PROTEIN KINASE KINASE KINASE; MITOGEN-ACTIVATED PROTEIN KINASE KINASE KINASE MLK4, HUMAN;

ANIMAL CELL; ARTICLE; CONTROLLED STUDY; GENE SILENCING; GLIOMA STEM CELL; HUMAN; HUMAN CELL; MESENCHYME CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; STEM CELL SELF-RENEWAL; ANIMAL; APOPTOSIS; BRAIN TUMOR; CANCER STEM CELL; ENZYMOLOGY; GENETICS; GLIOMA; MESENCHYMAL STROMA CELL; METABOLISM; PATHOLOGY; PHOSPHORYLATION; SIGNAL TRANSDUCTION;

ANIMALS; APOPTOSIS; BRAIN NEOPLASMS; GENE SILENCING; GLIOMA; HUMANS; MAP KINASE KINASE KINASES; MESENCHYMAL STROMAL CELLS; MICE; NEOPLASTIC STEM CELLS; NF-KAPPA B; PHOSPHORYLATION; SIGNAL TRANSDUCTION;

EID: 84958658738     PISSN: 15356108     EISSN: 18783686     Source Type: Journal    
DOI: 10.1016/j.ccell.2016.01.005     Document Type: Article

References (56)

1. Abi Saab W.F., Brown M.S., Chadee D.N. MLK4beta functions as a negative regulator of MAPK signaling and cell invasion. Oncogenesis 2012, 1:e6.
2. Badr C.E., Niers J.M., Tjon-Kon-Fat L.A., Noske D.P., Wurdinger T., Tannous B.A. Real-time monitoring of nuclear factor kappaB activity in cultured cells and in animal models. Mol. Imaging 2009, 8:278-290.
3. Bao S., Wu Q., McLendon R.E., Hao Y., Shi Q., Hjelmeland A.B., Dewhirst M.W., Bigner D.D., Rich J.N. Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature 2006, 444:756-760.
4. Baud V., Karin M. Is NF-kappaB a good target for cancer therapy? Hopes and pitfalls. Nat. Rev. Drug Discov. 2009, 8:33-40.
5. Beier D., Schulz J.B., Beier C.P. Chemoresistance of glioblastoma cancer stem cells-much more complex than expected. Mol. Cancer 2011, 10:128.
6. Bhat K.P., Balasubramaniyan V., Vaillant B., Ezhilarasan R., Hummelink K., Hollingsworth F., Wani K., Heathcock L., James J.D., Goodman L.D., et al. Mesenchymal differentiation mediated by NF-kappaB promotes radiation resistance in glioblastoma. Cancer Cell 2013, 24:331-346.
7. Bivona T.G., Hieronymus H., Parker J., Chang K., Taron M., Rosell R., Moonsamy P., Dahlman K., Miller V.A., Costa C., et al. FAS and NF-kappaB signalling modulate dependence of lung cancers on mutant EGFR. Nature 2011, 471:523-526.
8. Bonavia R., Inda M.M., Vandenberg S., Cheng S.Y., Nagane M., Hadwiger P., Tan P., Sah D.W., Cavenee W.K., Furnari F.B. EGFRvIII promotes glioma angiogenesis and growth through the NF-kappaB, interleukin-pathway. Oncogene 2012, 31:4054-4066.
9. Brach M.A., Hass R., Sherman M.L., Gunji H., Weichselbaum R., Kufe D. Ionizing radiation induces expression and binding activity of the nuclear factor kappa B. J. Clin. Invest. 1991, 88:691-695.
10. Candolfi M., King G.D., Yagiz K., Curtin J.F., Mineharu Y., Muhammad A.K., Foulad D., Kroeger K.M., Barnett N., Josien R., et al. Plasmacytoid dendritic cells in the tumor microenvironment: immune targets for glioma therapeutics. Neoplasia 2012, 14:757-770.
11. Capper D., Gaiser T., Hartmann C., Habel A., Mueller W., Herold-Mende C., von Deimling A., Siegelin M.D. Stem-cell-like glioma cells are resistant to TRAIL/Apo2L and exhibit down-regulation of caspase-by promoter methylation. Acta Neuropathol. 2009, 117:445-456.
12. Carro M.S., Lim W.K., Alvarez M.J., Bollo R.J., Zhao X., Snyder E.Y., Sulman E.P., Anne S.L., Doetsch F., Colman H., et al. The transcriptional network for mesenchymal transformation of brain tumours. Nature 2010, 463:318-325.
13. Chaichana K.L., McGirt M.J., Laterra J., Olivi A., Quinones-Hinojosa A. Recurrence and malignant degeneration after resection of adult hemispheric low-grade gliomas. J. Neurosurg. 2010, 112:10-17.
14. Chen J., Li Y., Yu T.S., McKay R.M., Burns D.K., Kernie S.G., Parada L.F. A restricted cell population propagates glioblastoma growth after chemotherapy. Nature 2012, 488:522-526.
15. Fan S., Gao M., Meng Q., Laterra J.J., Symons M.H., Coniglio S., Pestell R.G., Goldberg I.D., Rosen E.M. Role of NF-kappaB signaling in hepatocyte growth factor/scatter factor-mediated cell protection. Oncogene 2005, 24:1749-1766.
16. Fan S., Meng Q., Laterra J.J., Rosen E.M. Scatter factor protects tumor cells against apoptosis caused by TRAIL. Anticancer Drugs 2010, 21:10-24.
17. Ferris R.L., Grandis J.R. NF-kappaB gene signatures and p53 mutations in head and neck squamous cell carcinoma. Clin. Cancer Res. 2007, 13:5663-5664.
18. Flavahan W.A., Wu Q., Hitomi M., Rahim N., Kim Y., Sloan A.E., Weil R.J., Nakano I., Sarkaria J.N., Stringer B.W., et al. Brain tumor initiating cells adapt to restricted nutrition through preferential glucose uptake. Nat. Neurosci. 2013, 16:1373-1382.
19. Gallego-Perez D., Higuita-Castro N., Denning L., DeJesus J., Dahl K., Sarkar A., Hansford D.J. Microfabricated mimics of in vivo structural cues for the study of guided tumor cell migration. Lab Chip 2012, 12:4424-4432.
20. Gallo K.A., Johnson G.L. Mixed-lineage kinase control of JNK and p38 MAPK pathways. Nat. Rev. Mol. Cell Biol. 2002, 3:663-672.
21. Gan H.K., Lappas M., Cao D.X., Cvrljevdic A., Scott A.M., Johns T.G. Targeting a unique EGFR epitope with monoclonal antibody 806 activates NF-kappaB and initiates tumour vascular normalization. J. Cell. Mol. Med. 2009, 13:3993-4001.
22. Goodwin C.R., Lal B., Ho S., Woodard C.L., Zhou X., Taeger A., Xia S., Laterra J. PTEN reconstitution alters glioma responses to c-Met pathway inhibition. Anticancer Drugs 2011, 22:905-912.
23. Greten F.R., Arkan M.C., Bollrath J., Hsu L.C., Goode J., Miething C., Goktuna S.I., Neuenhahn M., Fierer J., Paxian S., et al. NF-kappaB is a negative regulator of IL-1beta secretion as revealed by genetic and pharmacological inhibition of IKKbeta. Cell 2007, 130:918-931.
24. Gu C., Banasavadi-Siddegowda Y.K., Joshi K., Nakamura Y., Kurt H., Gupta S., Nakano I. Tumor-specific activation of the C-JUN/MELK pathway regulates glioma stem cell growth in a p53-dependent manner. Stem Cells 2013, 31:870-881.
25. Guvenc H., Pavlyukov M.S., Joshi K., Kurt H., Banasavadi-Siddegowda Y.K., Mao P., Hong C., Yamada R., Kwon C.H., Bhasin D., et al. Impairment of glioma stem cell survival and growth by a novel inhibitor for Survivin-Ran protein complex. Clin. Cancer Res. 2013, 19:631-642.
26. Halliday J., Helmy K., Pattwell S.S., Pitter K.L., LaPlant Q., Ozawa T., Holland E.C. In vivo radiation response of proneural glioma characterized by protective p53 transcriptional program and proneural-mesenchymal shift. Proc. Natl. Acad. Sci. USA 2014, 111:5248-5253.
27. Hemmati H.D., Nakano I., Lazareff J.A., Masterman-Smith M., Geschwind D.H., Bronner-Fraser M., Kornblum H.I. Cancerous stem cells can arise from pediatric brain tumors. Proc. Natl. Acad. Sci. USA 2003, 100:15178-15183.
28. Hnisz D., Abraham B.J., Lee T.I., Lau A., Saint-Andre V., Sigova A.A., Hoke H.A., Young R.A. Super-enhancers in the control of cell identity and disease. Cell 2013, 155:934-947.
29. Irimia D., Toner M. Spontaneous migration of cancer cells under conditions of mechanical confinement. Integr. Biol. 2009, 1:506-512.
30. Jeon H.M., Kim S.H., Jin X., Park J.B., Kim S.H., Joshi K., Nakano I., Kim H. Crosstalk between glioma-initiating cells and endothelial cells drives tumor progression. Cancer Res. 2014, 74:4482-4492.
31. Johnson J., Nowicki M.O., Lee C.H., Chiocca E.A., Viapiano M.S., Lawler S.E., Lannutti J.J. Quantitative analysis of complex glioma cell migration on electrospun polycaprolactone using time-lapse microscopy. Tissue Eng. Part C Methods 2009, 15:531-540.
32. Joshi K., Banasavadi-Siddegowda Y., Mo X., Kim S.H., Mao P., Kig C., Nardini D., Sobol R.W., Chow L.M., Kornblum H.I., et al. MELK-dependent FOXM1 phosphorylation is essential for proliferation of glioma stem cells. Stem Cells 2013, 31:1051-1063.
33. Kaper F., Dornhoefer N., Giaccia A.J. Mutations in the PI3K/PTEN/TSC2 pathway contribute to mammalian target of rapamycin activity and increased translation under hypoxic conditions. Cancer Res. 2006, 66:1561-1569.
34. Locatelli M., Ferrero S., Martinelli Boneschi F., Boiocchi L., Zavanone M., Maria Gaini S., Bello L., Valentino S., Barbati E., Nebuloni M., et al. The long pentraxin PTX3 as a correlate of cancer-related inflammation and prognosis of malignancy in gliomas. J. Neuroimmunol. 2013, 260:99-106.
35. Mani S.A., Guo W., Liao M.J., Eaton E.N., Ayyanan A., Zhou A.Y., Brooks M., Reinhard F., Zhang C.C., Shipitsin M., et al. The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell 2008, 133:704-715.
36. Mao P., Joshi K., Li J., Kim S.H., Li P., Santana-Santos L., Luthra S., Chandran U.R., Benos P.V., Smith L., et al. Mesenchymal glioma stem cells are maintained by activated glycolytic metabolism involving aldehyde dehydrogenase 1A3. Proc. Natl. Acad. Sci. USA 2013, 110:8644-8649.
37. Martini M., Russo M., Lamba S., Vitiello E., Crowley E.H., Sassi F., Romanelli D., Frattini M., Marchetti A., Bardelli A. Mixed lineage kinase MLK4 is activated in colorectal cancers where it synergistically cooperates with activated RAS signaling in driving tumorigenesis. Cancer Res. 2013, 73:1912-1921.
38. Marusiak A.A., Edwards Z.C., Hugo W., Trotter E.W., Girotti M.R., Stephenson N.L., Kong X., Gartside M.G., Fawdar S., Hudson A., et al. Mixed lineage kinases activate MEK independently of RAF to mediate resistance to RAF inhibitors. Nat. Commun. 2014, 5:3901.
39. Miyazaki T., Pan Y., Joshi K., Purohit D., Hu B., Demir H., Mazumder S., Okabe S., Yamori T., Viapiano M., et al. Telomestatin impairs glioma stem cell survival and growth through the disruption of telomeric G-quadruplex and inhibition of the proto-oncogene, c-Myb. Clin. Cancer Res. 2012, 18:1268-1280.
40. Moody S.E., Perez D., Pan T.C., Sarkisian C.J., Portocarrero C.P., Sterner C.J., Notorfrancesco K.L., Cardiff R.D., Chodosh L.A. The transcriptional repressor snail promotes mammary tumor recurrence. Cancer Cell 2005, 8:197-209.
41. Nurwidya F., Takahashi F., Murakami A., Takahashi K. Epithelial mesenchymal transition in drug resistance and metastasis of lung cancer. Cancer Res. Treat. 2012, 44:151-156.
42. Oh M.C., Kim J.M., Safaee M., Kaur G., Sun M.Z., Kaur R., Celli A., Mauro T.M., Parsa A.T. Overexpression of calcium-permeable glutamate receptors in glioblastoma derived brain tumor initiating cells. PLoS One 2012, 7:e47846.
43. Omuro A., DeAngelis L.M. Glioblastoma and other malignant gliomas: a clinical review. JAMA 2013, 310:1842-1850.
44. Petrie R.J., Doyle A.D., Yamada K.M. Random versus directionally persistent cell migration. Nat. Rev. Mol. Cell Biol. 2009, 10:538-549.
45. Phillips H.S., Kharbanda S., Chen R., Forrest W.F., Soriano R.H., Wu T.D., Misra A., Nigro J.M., Colman H., Soroceanu L., et al. Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis. Cancer Cell 2006, 9:157-173.
46. Sanchez-Tillo E., Liu Y., de Barrios O., Siles L., Fanlo L., Cuatrecasas M., Darling D.S., Dean D.C., Castells A., Postigo A. EMT-activating transcription factors in cancer: beyond EMT and tumor invasiveness. Cell. Mol. Life Sci. 2012, 69:3429-3456.
47. Shirkoohi R. Epithelial mesenchymal transition from a natural gestational orchestration to a bizarre cancer disturbance. Cancer Sci. 2013, 104:28-35.
48. Singh S.K., Clarke I.D., Terasaki M., Bonn V.E., Hawkins C., Squire J., Dirks P.B. Identification of a cancer stem cell in human brain tumors. Cancer Res. 2003, 63:5821-5828.
49. Singh S.K., Hawkins C., Clarke I.D., Squire J.A., Bayani J., Hide T., Henkelman R.M., Cusimano M.D., Dirks P.B. Identification of human brain tumour initiating cells. Nature 2004, 432:396-401.
50. Suva M.L., Rheinbay E., Gillespie S.M., Patel A.P., Wakimoto H., Rabkin S.D., Riggi N., Chi A.S., Cahill D.P., Nahed B.V., et al. Reconstructing and reprogramming the tumor-propagating potential of glioblastoma stem-like cells. Cell 2014, 157:580-594.
51. Tafani M., Di Vito M., Frati A., Pellegrini L., De Santis E., Sette G., Eramo A., Sale P., Mari E., Santoro A., et al. Pro-inflammatory gene expression in solid glioblastoma microenvironment and in hypoxic stem cells from human glioblastoma. J. Neuroinflammation 2011, 8:32.
52. Tanaka K., Babic I., Nathanson D., Akhavan D., Guo D., Gini B., Dang J., Zhu S., Yang H., De Jesus J., et al. Oncogenic EGFR signaling activates an mTORC2-NF-kappaB pathway that promotes chemotherapy resistance. Cancer Discov. 2011, 1:524-538.
53. Verhaak R.G., Hoadley K.A., Purdom E., Wang V., Qi Y., Wilkerson M.D., Miller C.R., Ding L., Golub T., Mesirov J.P., et al. Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell 2010, 17:98-110.
54. Vescovi A.L., Galli R., Reynolds B.A. Brain tumour stem cells. Nat. Rev. Cancer 2006, 6:425-436.
55. Yamamoto M., Taguchi Y., Ito-Kureha T., Semba K., Yamaguchi N., Inoue J. NF-kappaB non-cell-autonomously regulates cancer stem cell populations in the basal-like breast cancer subtype. Nat. Commun. 2013, 4:2299.
56. Zhong J., Paul A., Kellie S.J., O'Neill G.M. Mesenchymal migration as a therapeutic target in glioblastoma. J. Oncol. 2010, 2010:430142.